First-in-Human trial tests inhaled gene therapy for rare lung disease
NCT ID NCT06633757
Summary
This early-stage study is testing an inhaled gene therapy called RCT1100 in adults with Primary Ciliary Dyskinesia (PCD) caused by specific DNAI1 gene mutations. The trial aims to see if the treatment improves mucus clearance from the lungs and is safe for participants. Researchers will measure how well the therapy works and monitor for any side effects in 12 adult volunteers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CILIARY DYSKINESIA (PCD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Copenhagen University Hospital - Rigshospitalet
Copenhagen, 2100, Denmark
-
Münster University Hospital, Albert-Schweitzer-Campus 1
Münster, North Rhine-Westphalia, 48149, Germany
-
UNC
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.